ripretinib (Qinlock)

following a full submission assessed under the end of life and orphan medicine process

ripretinib (Qinlock®) is not recommended for use within NHSScotland.

Indication under review: for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.

In a randomised, double-blind, phase III study, ripretinib significantly improved progression free survival compared with placebo in patients with advanced GIST who had received treatment with at least three prior kinase inhibitors.

The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting. The submitting company has indicated their intention to make a resubmission.